PRT2527

DRUG2 trials

Sponsors

Prelude Therapeutics

Conditions

Acute Myeloid Leukemia (AML)Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Castrate Resistant Prostate CancerChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Chronic Myelomonocytic Leukemia (CMML)Diffuse Large B-cell Lymphoma (DLBCL)Hormone Receptor Positive HER2 Negative Breast CancerMDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome

Phase 1

A Study of PRT2527 in Participants With Advanced Solid Tumors

CompletedNCT05159518

Prelude TherapeuticsCastrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer +2

Start: 2022-02-14End: 2023-12-06Updated: 2023-12-11

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

CompletedNCT05665530

Prelude TherapeuticsAcute Myeloid Leukemia (AML), Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) +9

Start: 2023-09-12End: 2026-01-21Updated: 2026-01-26

Related Papers

Abstract 5410: CDK9 pharmacological inhibition has antitumor activity in marginal zone lymphoma models and can improve the effects of BTK, PI3K, and BCL2 inhibitors

Cancer Research2025-04-21

Selective SMARCA2 Degradation Promotes Leukemic Differentiation and Synergizes with CDK9 Inhibition to Potently Induce Death in Pre-Clinical Models of Acute Myeloid Leukemia

Blood2024-11-051 citations

Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Blood2024-11-05

Abstract 5966: PRT2527, a novel highly selective cyclin-dependent kinase 9 (CDK9) inhibitor, has potent antitumor activity in combination with BTK and BCL2 inhibition in various lymphoid malignancies

Cancer Research2024-03-222 citations

Abstract C164: A phase 1 dose-escalation study of PRT2527, a cyclin-dependent kinase 9 (CDK9) inhibitor, in adult patients with advanced solid tumors: An updated analysis

Molecular Cancer Therapeutics2023-12-011 citations

PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Antitumor Activity in Combination with BTK and BCL2 Inhibition in Various Lymphoid Malignancies

Blood2023-11-022 citations

A Phase 1 Study Evaluating PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Select Relapsed/Refractory B-Cell Malignancies

Blood2023-11-02

A PHASE 1 STUDY EVALUATING PRT2527, A POTENT AND HIGHLY SELECTIVE CDK9 INHIBITOR, IN PATIENTS WITH SELECT RELAPSED/REFRACTORY B‐CELL MALIGNANCIES

Hematological Oncology2023-06-011 citations

Abstract CT173: A phase 1, open-label, multicenter, dose-escalation study of PRT2527, a cyclin-dependent kinase 9 (CDK9) inhibitor, in adult patients (pts) with advanced solid tumors

Cancer Research2023-04-143 citations